Problems › Too Dependent on One Customer › Healthcare Providers
Concentration is only a problem in proportion to how easily the customer could leave, which is a question about switching costs rather than about percentages. This page works through it for healthcare providers specifically — including an unedited excerpt from a real analysis of a healthcare provider.
Concentration is only a problem in proportion to how easily the customer could leave, which is a question about switching costs rather than about percentages. For healthcare providers, this shows up in a particular place. The numbers that carry the answer are cost per episode and payer mix, and the complication specific to this industry is that downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. The general version of this problem and the one you are actually in have different first moves.
A customer at 40% of revenue is dangerous or fine depending entirely on the structure underneath. If they can replace you within a quarter, that is an existential exposure. If replacing you means re-engineering their operation, it is a strong position that happens to look concentrated.
The trap is that concentration usually comes with worse economics — the large customer negotiates harder, demands more service and pays later — so the risk and the margin damage arrive together. Diluting concentration by growing elsewhere is slow; the faster lever is usually repricing the dependency to reflect the risk being carried.
It is also worth separating revenue concentration from contribution concentration. They can point in opposite directions, and the second is the one that would actually hurt.
These three together are the signature. One on its own usually points somewhere else.
✓ One customer exceeds a quarter of revenue
✓ That customer has materially better terms than everyone else
✓ Losing them would require immediate cost action rather than a plan
The move that usually makes it worse. Chasing volume elsewhere to dilute the percentage, which adds cost while leaving the dependency intact.
It is for you if you run or finance a healthcare provider and one customer exceeds a quarter of revenue. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Proprietary EFF Methodology, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
There is no threshold that means much on its own. What matters is how quickly they could replace you and what happens to your fixed costs if they do. Both are answerable.
Rarely on concentration grounds alone, and often on margin grounds. If the largest account is also the worst-priced, the concentration problem and the margin problem have the same fix.
Increase what it would cost them to leave, and reprice the exposure. Growing a second segment is the right long answer and does not help within the notice period you actually have.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.